Clinical Trials
29 trialsNCT07608458 2026-05-27
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
Phase NA Not yet recruiting
NCT07606599 2026-05-26
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07582315 2026-05-22
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07599995 2026-05-20
GENE
Sir Run Run Shaw Hospital
Phase 2 Not yet recruiting
NCT07561775 2026-05-01
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Tongji Hospital
Phase 2 Not yet recruiting
NCT07532759 2026-04-16
Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice
Fudan University
Phase NA Not yet recruiting
NCT06622057 2026-04-14
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
InnoPharmax Inc.
Phase 3 Not yet recruiting
NCT04910386 2026-03-25
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines
Phase 2 Not yet recruiting
NCT07437287 2026-02-27
CROCOBIL
UNICANCER
Phase 2/3 Not yet recruiting
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT07169916 2025-09-12
YJ-BTC
Fudan University
Phase NA Not yet recruiting
NCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT07160283 2025-09-08
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT07129018 2025-08-19
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07109167 2025-08-07
The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT07099794 2025-08-01
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07003815 2025-06-04
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT06993025 2025-05-28
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06919848 2025-04-09
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
Phase 2 Not yet recruiting
NCT06903273 2025-03-30
TisGCS for BTC
National Cheng-Kung University Hospital
Phase 2 Not yet recruiting
NCT06818773 2025-02-10
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
Eastern Hepatobiliary Surgery Hospital
Phase 4 Not yet recruiting
NCT06654947 2024-12-16
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06662877 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Phase 2/3 Not yet recruiting
NCT06569225 2024-08-26
NEOLANGIO
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06531291 2024-07-31
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
Phase 2 Not yet recruiting
NCT06502080 2024-07-17
RADITOP
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06389500 2024-04-29
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT06375954 2024-04-19
EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)
Hospital Universitari de Bellvitge
Phase NA Not yet recruiting
NCT06037655 2023-09-14
Modified
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting